Skip to main content
Equibles
BIO logo

BIO · Bio-Rad Laboratories, Inc. · Metrics

Track BIO — free

Use BIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$372.18 -12.22 (-3.18%) At close · Oct 30 Q2 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$9.95B
Shares
26.74M
Volume · Oct 30 183.13K Avg daily vol (3M) 254.36K

BIO metrics

104 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$372.18
Market cap
$9.95B

Price action

20 metrics
Price change (1W)
+0.6%
Price change (30D)
+4.7%
Price change (3M)
+14.3%
Price change (6M)
+45.1%
Price change (YTD)
+22.8%
Price change (1Y)
+22.2%
Trailing year
Price change (5Y)
-53.2%
52-week high
$390.34
52-week low
$241.71
Change from 52-week high
-4.7%
Change from 52-week low
+54.0%
Annualized volatility
36.4%
Annualized volatility (3M)
28.9%
Beta
0.7
RSI (14D)
51.6
Price vs SMA 50
-0.7%
Price vs SMA 200
+18.8%
Avg volume (3M)
254,362
Relative volume
0.7
Average dollar volume
$93.98M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
26.74M

Valuation

12 metrics
P / E (TTM)
45.4
Trailing earnings · reciprocal yield 2.2%
PEG ratio
2.4
EV / revenue
3.7×
reciprocal yield 27.2%
EV / EBITDA
24.5×
reciprocal yield 4.1%
EV / EBIT
179.6×
reciprocal yield 0.6%
P / sales
3.8×
reciprocal yield 26.0%
P / book
1.4
reciprocal yield 72.1%
FCF yield
3.5%
TTM · current market cap
Buyback yield
1.3%
P / FCF
28.2
reciprocal yield 3.5%
P / operating cash flow
20.2
reciprocal yield 5.0%
Earnings yield
2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
29.3×
reciprocal yield 3.4%
P / E historical average (5Y)
20.9×
reciprocal yield 4.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.3%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
51.9%
Operating margin
2.1%
Trailing 12 months
Net margin
8.6%
Gross profit (TTM)
$1.34B
Operating profit (TTM)
$53.10M
Net income (TTM)
$222.40M
Trailing 12 months
Diluted EPS (TTM)
$8.19
FCF margin
13.6%
Effective tax rate
36.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$96.14
Gross profit per diluted share (TTM)
$49.90
Operating profit per diluted share (TTM)
$2.00
EBITDA per diluted share (TTM)
$12.66
Net income per diluted share (TTM)
$8.23
Operating cash flow per diluted share (TTM)
$18.28
Free cash flow per diluted share (TTM)
$13.10
Capital expenditures per diluted share (TTM)
$5.18
R&D per diluted share (TTM)
$9.86
Stock compensation per diluted share (TTM)
$2.24
Book value per share
$46.45

Growth

11 metrics
Revenue growth YoY
-0.1%
Year over year
Net income growth YoY
+16.9%
Revenue (TTM)
$2.59B
Trailing 12 months
EPS growth YoY
+18.7%
Shares change YoY
-1.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-2.7%
Revenue CAGR (5Y)
+0.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-26.1%
FCF CAGR (3Y)
+66.2%
FCF CAGR (5Y)
-4.7%

Quality

14 metrics
Return on equity
3.1%
Return on assets
2.2%
Debt / equity
0.2
Current ratio
3.1
EBITDA (TTM)
$382.33M
Free cash flow (TTM)
$353.10M
Quick ratio
2.3
Interest coverage
1.1
Net debt / EBITDA
-1.6
Return on invested capital
0.5%
Trailing 12 months
Net cash
$414.80M
Latest balance sheet
Cash & equivalents
$517.00M
Total assets
$10.25B
Total debt
$1.20B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$492.60M
Capital expenditures (TTM)
$139.50M
R&D (TTM)
$265.70M
SG&A (TTM)
$852.20M
Stock compensation (TTM)
$60.30M
R&D / revenue
10.3%
Stock compensation / revenue
2.3%

Ownership (13F)

9 metrics
13F filers
405
13F filer change QoQ
+3
Institutional ownership
72.8%
Conviction holders (share of 13F filers)
1.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-4.5%
Holder tenure
15.8
Price vs estimated holder cost
+0.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.5%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 12208 CUSIP 090572207 13F (30d) 147 filings 120 filers Visit website Investor relations